These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1145 related articles for article (PubMed ID: 25757678)

  • 1. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
    Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib in the treatment of non-small-cell lung cancer.
    Forde PM; Rudin CM
    Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib in the treatment of non--small-cell lung cancer.
    Rothschild SI; Gautschi O
    Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ALK-positive non-small cell lung cancer.
    Bang YJ
    Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
    Facchinetti F; Rossi G; Bria E; Soria JC; Besse B; Minari R; Friboulet L; Tiseo M
    Cancer Treat Rev; 2017 Apr; 55():83-95. PubMed ID: 28342334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH
    Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
    Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
    Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
    Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
    Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
    Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.